JPMorgan lowered the firm’s price target on Solid Biosciences (SLDB) to $11 from $12 and keeps an Overweight rating on the shares. The firm updated models in the small-cap biotechnology space.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLDB:
- Solid Biosciences price target raised to $20 from $16 at H.C. Wainwright
- Solid Biosciences: Promising Gene Therapy Advancements and Strategic Pipeline Expansion Justify Buy Rating
- Solid Biosciences: Positive DMD Program Developments and Strong Financial Position Justify Buy Rating
- Solid Biosciences files to sell 364,990 shares of common stock for holders
- Solid Biosciences files to sell 975,496 shares of common stock for holders